Analysis of mCRPC patients circulating tumor cells (CTCs) (80) revealed PD-L1 protein in over 50% of CTCs, PD-L1 mRNA overexpression in 48% of patients, and both PD-L1-positive and -negative CTCs in 37.5% of cases, highlighting tumor heterogeneity. This evidence concerns the gene CD274 and neoplasm.